Xilio Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
8.7%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$2.59next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Pipeline Update | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly2KTarget: Early 2028
Cash and Cash Equivalents Quarterly150.3M
Watch Items
- XTX501 IND SubmissionTrigger: Mid-2026Action: Monitor FDA clearance and subsequent Phase 1 trial initiation in H2 2026.
- STEAP1 Masked T Cell Engager Development Candidate NominationTrigger: Q2 2026Action: Track candidate nomination and transition into IND-enabling studies.
- Gilead IL-12 Option Data Package DeliveryTrigger: H1 2027Action: Evaluate clinical data package for efarindodekin alfa to trigger Gilead's opt-in decision.
Research as of 20 Jun 2026